Диссертация (Разработка подходов к стандартизации инновационного лекарственного средства в рамках реализации программы стратегии фарма 2020), страница 14

// Microbiol. Immunol. – 1985. – № 1(29). – P. 65–74.60. Aso H. Antiviral activity of carboxyethylgermanium sesquioxide (Ge-132) inmice infected with influenza virus / H. Aso et al. // J. Biol. Response Mod. – 1989. –№ 2(8). – P. 180–189.61. Badger A. M. Generation of suppressor cells in normal rats by treatment withspirogermanium, a novel heterocyclic anticancer drug / A. M. Badger, C. K.Mirabelli, M. Di Martino. // Immunopharmacology. – 1985. – № 3 (10). – P. 201–207.62.

Brutkiewicz R.R. Biological activities and antitumor mechanism of animmunopotentiating organogermanium compound / R.R. Brutkiewicz, F. Suzuki //Vivo Athens Greece. – 1987. – № 1. – P. 189–203.63. Budman D.R. Phase I trial of spirogermanium given by infusion in a multipledose schedule / D.R.

Budman et al. // Cancer Treat. Rep. – 1982. – № 1(66). – P.173–175.64. Chang Ki K. Effects of Geranti (Biosynthesized Organic Germanium) on theAnticancer and Immuno-enhancement / Ki K. Chang, Ho J. Cha, Ku K. Jong //Chungbuk Natl. Univ. Korea Res. Inst. Anim. Med. – 1995.65. Choi S.

Synthesis and biological evaluation of water-soluble organogermanium /S. Choi et al. // Eur. J. Med. Chem. – 2010. – № 4(45). – P. 1654–1656.66. Crooks R. J. Valaciclovir a review of its potential in the management of genitalherpes / R. J. Crooks // Antiviral Chem. Chemother. – 1995. – 6 (Suppl. 1). – P. 3944.67. Crumpacker C. S. Ganciclovir. / C. S.

Crumpacker // N. Engl. J. Med. – 1996. –№335. – P. 721-729.11868. De Clercq Е. Review. Antiviral prodrugs the development of successful prodrugstrategies for antiviral chemotherapy / Е. De Clercq, H. J. Field // British Journal ofPharmacology. – 2006.

– №147. – P. 1-11. – published online 14 November 2005.69. De Clercq E. Antiviral activity of phosphonylmethoxyalkyl derivatives of purineand pyrimidines / E. De Clercq // Antiviral Res. – 1987. – №8. P. 261-272.70. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J. & Maudgal P. C., Anovel selective broad-spectrum anti-DNA virus agent / E. De Clercq et al.

// Nature. –1986. – №323. – P. 464-467.71. Elion G. B. Mechanism of action and selectivity of acyclovir / G. B. Elion // Am.J. Med. – 1982. – № 1(73). – P. 7 –13.72. Fennel R.W. History of IUPAC, 1919–1987 / R.W. Fennel. – Oxford: BlackwellScience Ltd, 1994.73. Fujii A. Effect of organic germanium compound (Ge-132) on experimentalosteoporosis in rats / A. Fujii et al. // Gen.

Pharmacol. – 1993. – № 6(24). – P. 1527–1532.74. Gerber G.B. Mutagenicity, carcinogenicity and teratogenicity of germaniumcompounds / G.B. Gerber, A. Léonard // Mutat. Res. – 1997. – № 3(387). – P. 141–146.75. Gilbert С., Julie Bestman-Smith, Guy Boivin Resistance of herpesviruses toantiviral drugs: clinical impacts and molecular mechanisms / C. Gilbert, J. BestmanSmith, G. Boivin // Drug Resist. Updat. – 2002.

– № 2(5). – P. 88–114.76. Goodman S. Therapeutic Effects of Organic Germanium / S. Goodman // Med.Hypothesis. – 1988. – № 3(26). – P. 207–215.77. Goudgaon N. М. Activity of Acyclic 6-(Phenilselenil)pyrimidine Nucleosidesagainst Human Immunodeficietncy Viruses in Primary Lymphocytes / N. М.Goudgaon and Schinazi R. F // J. Med. Chem. – 1991. – №34.

– P. 3305-3309.78. Harnden M. R. Synthesis of Novel Series of Acyclic Nucleoside Analogues / M.R. Harnden, S. Baley, M. R. Boyd // Top. Med. Chem. Proc. 4th SCI-RSC Med.Chem. Symp. Cambridge – 6th-9th. Sept. 1988. – London. – P. 213-244.79. Hasan A. Synthesis and Biological Studies of Unsaturated AcyclonucleosideAnalogues of S-Adenosil-L-homocysteine Hydrolase Inhibitors.

/ A. Hasan and P. C.Srivastava // J. Med. Chem. – 1992. – №35. – P. 1435-1439.80. Henry M.C. Toxicity of spirogermanium in mice and dogs after iv or imadministration / M.C. Henry et al. // Cancer Treat. Rep. – 1980. – № 12(64). – P.1207–1210.11981. Ho C.C. Effects of organogermanium compound 2-carboxyethyl germaniumsesquioxide on cardiovascular function and motor activity in rats / C.C.

Ho, Y.F.Chern, M.T. Lin // Pharmacology. – 1990. – № 5(41). – P. 286–291.82. ICH Expert Working Group et al. Q1A (R2) Stability Testing of New DrugSubstances and Products //International Conference on Harmonisation of TechnicalRequirements for the Registration of Pharmaceuticals for Human Use. – 2003.83. Jeannot F.

Synthesis and antiviral evaluation of3-C-trifluoromethyl nucleosidederivatives bearing adenine as the base / F. Jeannot, C. Mathe, G. Gosselin //Nucleosides, Nucleotides & Nucleic Acids. – 2001. – 20(4-7) – P. 755-758.84. Jong-Sung Lee Oral single- and repeated-dose toxicity studies on Geranti Bio-Geyeast, organic germanium fortified yeasts, in rats / Lee Jong-Sung et al. // J. Toxicol.Sci. – 2004.

– № 5 (29). – P. 555–569.85. Keppeler K. Synthesis and Antiviral Activity of Acyclic Derivatives of 5-Etyl-2’Deoxyuridine / K. Keppeler, G. Kiefer, E. De Clercq // Arch. Pharm. – 1986. –№319. – P. 360-365.86. Kim S. E Acyclovir-Resistant Herpes Simplex Virus Infections in Patients withthe Acquired Immunodeficiency Syndrome / S. E. Kim et al. // N. Engl.

J. Med. –1989. – №320. – P. 293–296.87. Lee Jong-Sung Oral single- and repeated-dose toxicity studies on Geranti Bio-Geyeast, organic germanium fortified yeasts, in rats / Jong-Sung Lee et al. // J. Toxicol.Sci. – 2004. – № 5 (29). – P. 555–569.88. Mirabelli C.K. Pharmacological activities of spirogermanium and otherstructurally related azaspiranes: effects on tumor cell and macrophage functions /C.K. Mirabelli et al.

// – Anticancer. Drug Des. – 1989. – № 3(4). – P. 231–242.89. Mironov V.F. Reactions of trichlorogermane with acrylic acid and its derivatives /V.F. Mironov, E.M. Berliner, T.K. Gar // Zhurnal Obshchei Khimii. – 1967. – № 37.– 911–912.90. Morfin F. Herpes simplex virus resistance to antiviral drugs / F. Morfin,D.Thouvenot // J.

Clin. Virol. – 2003. – № 1 (26). – P. 29–37.91. Myron L.J. Resistance of Herpes Simplex Virus Infections to NucleosideAnalogues in HIV-Infected Patients / L.J. Myron, T.H. Bacon, J.J. Leary // Clin.Infect. Dis. – 2004. – № 5(39). – P. 248–257.92. Phan Dana D. Intra- and Interindividual Variabilities of Valacyclovir OralBioavailability and Effect of Coadministration of an hPEPT1 Inhibitor / Dana D.Phan et al.

// Antimicrob. Agents Chemother. – 2003. – № 7(47). – P. 2351–2353.12093. Raisin J. Toxicity of an organic Germanium compound: deleterious consequencesof a “natural remedy” / J. Raisin et al. // Schweiz. Med. Wochenschr. – 1992. – №1(122) – P. 11–13.94. Robins M. J. Nucleic Acid Related Compounds. 47: Synthesis and BiologicalActivities of Pyrimidine and Purine «Acyclic» Nucleoside Analogues / M.

J. Robins,P. W. Hatfield, J. Balzarini, and E. De Clercq // J. Med. Chem. – 1984. – №27. – P.1486-1492.95. Rosenthal K.S. Tromantadine: inhibitor of early and late events in herpes simplexvirus replication / K.S. Rosenthal et al. // Antimicrob. Agents Chemother. – 1982. –№ 6 (22). – P.

1031–1036.96. Schulz T.F. Antivirale Chemotherapie / T.F. Schulz., D. Falke // Med. Mikrobiol.Infekt. – 2012. – P. 763–773.97. Simões S. Modular Hydrogels for Drug Delivery / S. Simões, A. Figueiras, F.Veiga // Journal of Biomaterials and Nanobiotechnology. – 2012. – №3. – P. 185199.98. Song W.J. Preparation of organic germanium by yeast cell / W.J. Song, S.C. Lee,T.K.

Oh // Kor J Appl Microbiol Biotechnol. – 1995. –. № 23(1). – P. 87.99. Suzuki F. Antitumor mechanisms of carboxyethyl-germanium sesquioxide (Ge132) in mice bearing Ehrlich ascites tumors / F. Suzuki // Gan To Kagaku Ryoho. –1987. – № 1(14). – P. 127–134.100. Suzuki F. Suppression of tumor growth by peritoneal macrophages isolated frommice treated with carboxyethylgermanium sesquioxide (Ge-132) / F. Suzuki // GanTo Kagaku Ryoho. – 1985. – № 12(11). – P. 2122–2128.101.

Suzuki F. Importance of T-cells and macrophages in the antitumor activity ofcarboxyethylgermanium sesquioxide (Ge-132). / F. Suzuki, R.R. Brutkiewicz., R.B.Pollard // Anticancer Res. – 1985. – № 5. – P. 479–483.102. Takeuchi A. Nephrotoxicity of Germanium Compounds: Report of a Case andReview of the Literature / A.

Takeuchi et al. // Nephron. – 1992. – № 4(60). – P.436–442.103. Tanaka H. A New Class of HIV-1-Specific 6-Substituted AcyclouridineDerivatives: Synthesis and Anti-HIV-l Activity of l-(2-Hydroxyetoxy)metyl.-6(phenylthio)thymine (HEPT) / H. Tanaka // J. Med. Chem. – 1991. – №34. – P. 349357.104. Tao S.H. Hazard assessment of germanium supplements / S.H. Tao, P.M.

Bolger// Regul. Toxicol. Pharmacol. – 1997. – № 3(25). – P. 211–219.121105. Tropé C. Phase II study of spirogermanium in advanced ovarian malignancy / C.Tropé et al. // Cancer Treat. Rep. – 1981. – № 1(65) – P. 119–120.106. Wakabayashi Y. Effect of germanium-132 on low-density lipoprotein oxidationand atherosclerosis in Kurosawa and Kusanagi hypercholesterolemic rabbits / Y.Wakabayashi // Biosci.